☆ 4.5 Article

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study

LUNG CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks et al.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients

Minjiang Chen et al.

Summary: The efficacy of immune checkpoint inhibitors for EGFR-mutant NSCLC is worth investigating. Propensity score matching showed that chemotherapy plus immunotherapy improved progression-free survival compared to chemotherapy alone, suggesting its potential usefulness for patients with EGFR-mutant NSCLC.

CLINICAL LUNG CANCER (2023)

添加到收藏夹

Article Oncology

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib

Maya N. White et al.

Summary: The optimal treatment for EGFR-mutated lung cancer after progression on osimertinib remains unclear. A retrospective study was conducted to evaluate the outcomes of patients who received platinum doublet chemotherapy alone or in combination with immunotherapy or bevacizumab. The results showed that adding immunotherapy to chemotherapy resulted in worse overall survival, while the addition of bevacizumab did not significantly affect survival.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Egbert F. Smit et al.

Summary: Combining osimertinib with MET inhibitor like tepotinib could potentially overcome resistance driven by MET amplification in NSCLC patients, and the ongoing study INSIGHT 2 aims to evaluate the efficacy and safety of this combination therapy for patients with acquired resistance to osimertinib due to MET amplification.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami et al.

Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Pasi A. Janne et al.

Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases

Malinda Itchins et al.

Summary: Limited real world data exist on the IMpower150 regimen, and this study adds to the knowledge base by demonstrating its efficacy in EGFR mutant patients, including those with CNS metastases. The overall response rate for all patients was 51%, and for EGFR mutant patients it was 52%, highlighting the positive outcomes of this treatment approach.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3trial

Shun Lu et al.

Summary: The study evaluated the efficacy and safety of sintilimab with or without IBI305, combined with pemetrexed and cisplatin, for treating EGFR mutated non-small-cell lung cancer patients. The interim analysis showed prolonged progression-free survival in patients treated with sintilimab plus IBI305 plus chemotherapy compared to chemotherapy alone.

LANCET ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure

J. Wang et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T. S. K. Mok et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Xiuning Le et al.

Summary: The VEGF and EGFR pathways play crucial roles in EGFR-mutant NSCLC, and dual inhibition of these two pathways can significantly improve patient outcomes.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu et al.

Summary: ORCHARD aims to characterize mechanisms of resistance to first-line osimertinib and explore treatments to overcome acquired resistance. The study's modular design allows for additional biomarker-directed cohorts and treatment options as understanding of osimertinib resistance mechanisms evolves.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy

Xin Yu et al.

Summary: After EGFR-TKI therapy failure, chemo-immunotherapy combinations achieved a higher objective response rate compared to chemo-antiangiogenesis combinations, but no significant difference was found in disease control rate and progression-free survival. For patients with EGFR T790M mutations, chemo-antiangiogenesis combinations may be the preferred therapeutic option, and platelet count could be a potential prognostic factor for patients after EGFR-TKI therapy failure.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

S. S. Ramalingam et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonesmall-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Alexis B. Cortot et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

A. J. Schoenfeld et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

The Intersection between Tumor Angiogenesis and Immune Suppression

Osama E. Rahma et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Oncology

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

Thanyanan Reungwetwattana et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Cell Biology

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Tatsuya Nagano et al.

CELLS (2018)

添加到收藏夹

Meeting Abstract Oncology

Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

G. Riely et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Alan Sandler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.